Acute rejection, occurring with a reported frequency of 50–70%, is still a dominating problem
after liver transplantation. Medication with ursodeoxycholic acid (UDCA) has beneficial …

Adjuvant treatment with ursodeoxycholic acid (UDCA) for liver-transplant recipients has
been reported to reduce the frequency of acute rejection episodes. To explore this effect …

Background/Aims: Acute rejection is still a major problem after liver transplantation.
Ursodeoxycholic acid has beneficial effects in cholestasis by reducing the expression of …

Steroid-resistant rejection continues to be a serious problem in liver transplantation. Since
ursodeoxycholic acid (UDCA) is beneficial in several cholestatic disorders and possesses in …

Acute rejection following orthotopic liver transplantation is a common problem despite
current immunosuppressive regimens. Ursodeoxycholic acid (UDCA) has been shown in …

There are many different causes of graft dysfunction and cholestasis after liver
transplantation. These include non-primary function, preservation and reperfusion injury …

Acute cellular rejection (ACR) after orthotopic liver transplantation occurs in 50% to 80% of
patients despite the recent advances in immunosuppressive therapy. Adjuvant use of …

Background. Prophylactic treatment with ursodeoxycholic acid (UDCA) has been reported to
reduce the incidence of acute rejection after liver transplantation compared with historical …

Background The nontoxic bile acid, ursodeoxycholic acid (UDCA), is an effective drug for the
treatment of different cholestatic conditions. Furthermore, an immunomodulatory capacity of …

As ursodeoxycholic acid (UDCA) delays the need for transplantation, this could result in
patients with more comorbid disease, therefore more likely to have a worse outcome …